Richard Adcock - 09 Sep 2021 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Signature
/s/ Steven Yang, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
09 Sep 2021
Net transactions value
-$42,516
Form type
4
Filing time
13 Sep 2021, 20:32:29 UTC
Next filing
08 Oct 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +8,620 +11% $0.000000 90,449 09 Sep 2021 Direct F1
transaction IBRX Common Stock Tax liability $42,516 -4,273 -4.7% $9.95 86,176 09 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -8,620 -5% $0.000000 163,800 09 Sep 2021 Common Stock 8,620 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

Remarks:

Exhibit 24 - Power of Attorney